Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary

Protalix BioTherapeutics announces that Dror Bashan, the Company's President and CEO, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023.

Positive

• Investors can gain insights from Dror Bashan's live corporate overview at the conference.

Negative

• None.

CARMIEL, Israel, Sept. 6, 2023  /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx^® plant cell–based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present on Wednesday, September 13, 2023 at 3:00 p.m. Eastern Daylight Time (EDT) at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is being held on September 11-13, 2023 at the Lotte New York Palace Hotel, New York City, NY.

Mr. Bashan will provide a live corporate overview at the conference, and will participate in one-on-one meetings with investors who are registered to attend the conference.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through a plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio^®, was approved by both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio.

Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others.

Investor Contact

Chuck Padala, Managing Director
LifeSci Advisors
+1-646-627-8390

Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301919041.html

SOURCE Protalix BioTherapeutics, Inc.

FAQ

When and where is the H.C. Wainwright 25th Annual Global Investment Conference?

The conference is being held on September 11-13, 2023 at the Lotte New York Palace Hotel, New York City, NY.

Who will be presenting at the conference?

Dror Bashan, the President and CEO of Protalix BioTherapeutics, will be presenting at the conference.

What can investors expect from Dror Bashan's presentation?

Investors can gain insights from Dror Bashan's live corporate overview at the conference.